SoftBank-Backed Guardant Health IPO: A Litmus Test for Cancer Gene Sequencing?

Adam Augusiak-Boro
Sep 13th, 2018
Guardant Health, which filed an S-1 on September 5, 2018 in anticipation of going public, is a precision oncology company that aims to improve the diagnosis and treatment of cancer through its proprietary gene sequencing technology. Founded in 2012 in the San Francisco Bay Area, Guardant has received over $500 million in private funding, most recently closing a $360 million round in May 2017 led by SoftBank’s Vision Fund. The company plans to list on the NASDAQ under the ticker “GH.” Timing, pricing and size of the offering are still TBA.
View more research reports

Join 100,000+ global shareholders and investors on EquityZen